SPRINT Share Price Performance
SEK 0.67
-0.71 (-51.45%)
Price SEK 0.67
Share PriceSEK 0.67
Sprint Bioscience AB (publ) Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 3 Fair Values set on narratives written by author
SPRINT Community Narratives
There are no narratives available yet.
Recent SPRINT News & Updates
Sprint Bioscience AB (publ) Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.21
- Gross Margin
- 60.05%
- Net Profit Margin
- -37.65%
- Debt/Equity Ratio
- 0%
Sprint Bioscience AB (publ) Competitors
Snowflake Analysis
About SPRINT
- Founded
- 2009
- Employees
- 36
- CEO
- WebsiteView website
Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden.
Market Insight
Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading
Swedish Market Performance
- 7 Days: 1.7%
- 3 Months: 2.4%
- 1 Year: -0.5%
- Year to Date: 2.9%
The market has climbed 1.7% in the last 7 days, lead by the Industrials sector with a gain of 2.6%. The market has been flat overall in the last year. As for the next few years, earnings are expected to grow by 16% per annum. Market details ›